Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C16H23NO2 |
| Molecular Weight | 261.3593 |
| Optical Activity | ( + ) |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC[C@@]1(OC[C@@H](O1)[C@@H]2CCCCN2)C3=CC=CC=C3
InChI
InChIKey=INOYCBNLWYEPSB-XHSDSOJGSA-N
InChI=1S/C16H23NO2/c1-2-16(13-8-4-3-5-9-13)18-12-15(19-16)14-10-6-7-11-17-14/h3-5,8-9,14-15,17H,2,6-7,10-12H2,1H3/t14-,15+,16-/m0/s1
CNS Activity
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2094124 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16169732 |
19.8 null [Ki] |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Synthesis, absolute configuration, and molecular modeling study of etoxadrol, a potent phencyclidine-like agonist. | 1988-12 |
|
| Discriminative stimulus and reinforcing properties of etoxadrol and dexoxadrol in monkeys. | 1982-01 |
|
| Clinical investigation of a new intravenous anesthetic--etoxadrol hydrochloride (CL-1848; U-37862A). | 1976-05-01 |
|
| Effects of intravenous anesthetics on continuous avoidance behavior in the rat. | 1976-02 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/5921
0.75 mg/kg
Route of Administration:
Intravenous
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C245
Created by
admin on Mon Mar 31 17:50:45 GMT 2025 , Edited by admin on Mon Mar 31 17:50:45 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
100000082113
Created by
admin on Mon Mar 31 17:50:45 GMT 2025 , Edited by admin on Mon Mar 31 17:50:45 GMT 2025
|
PRIMARY | |||
|
SIQ2UWR01K
Created by
admin on Mon Mar 31 17:50:45 GMT 2025 , Edited by admin on Mon Mar 31 17:50:45 GMT 2025
|
PRIMARY | |||
|
2796
Created by
admin on Mon Mar 31 17:50:45 GMT 2025 , Edited by admin on Mon Mar 31 17:50:45 GMT 2025
|
PRIMARY | |||
|
C81415
Created by
admin on Mon Mar 31 17:50:45 GMT 2025 , Edited by admin on Mon Mar 31 17:50:45 GMT 2025
|
PRIMARY | |||
|
288020
Created by
admin on Mon Mar 31 17:50:45 GMT 2025 , Edited by admin on Mon Mar 31 17:50:45 GMT 2025
|
PRIMARY | |||
|
ETOXADROL
Created by
admin on Mon Mar 31 17:50:45 GMT 2025 , Edited by admin on Mon Mar 31 17:50:45 GMT 2025
|
PRIMARY | |||
|
DTXSID10912322
Created by
admin on Mon Mar 31 17:50:45 GMT 2025 , Edited by admin on Mon Mar 31 17:50:45 GMT 2025
|
PRIMARY | |||
|
3215
Created by
admin on Mon Mar 31 17:50:45 GMT 2025 , Edited by admin on Mon Mar 31 17:50:45 GMT 2025
|
PRIMARY | |||
|
14208380
Created by
admin on Mon Mar 31 17:50:45 GMT 2025 , Edited by admin on Mon Mar 31 17:50:45 GMT 2025
|
PRIMARY | |||
|
28189-85-7
Created by
admin on Mon Mar 31 17:50:45 GMT 2025 , Edited by admin on Mon Mar 31 17:50:45 GMT 2025
|
PRIMARY | |||
|
C084821
Created by
admin on Mon Mar 31 17:50:45 GMT 2025 , Edited by admin on Mon Mar 31 17:50:45 GMT 2025
|
PRIMARY | |||
|
CHEMBL305904
Created by
admin on Mon Mar 31 17:50:45 GMT 2025 , Edited by admin on Mon Mar 31 17:50:45 GMT 2025
|
PRIMARY | |||
|
SUB07341MIG
Created by
admin on Mon Mar 31 17:50:45 GMT 2025 , Edited by admin on Mon Mar 31 17:50:45 GMT 2025
|
PRIMARY | |||
|
m5202
Created by
admin on Mon Mar 31 17:50:45 GMT 2025 , Edited by admin on Mon Mar 31 17:50:45 GMT 2025
|
PRIMARY | Merck Index |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)